Pharvaris Reports Q1 2025 Financials and Advances HAE Treatment Trials

An announcement from Pharvaris ( (PHVS) ) is now available.

On May 13, 2025, Pharvaris announced its financial results for the first quarter of 2025 and provided business updates. The company is advancing its pivotal Phase 3 studies, CHAPTER-3 and RAPIDe-3, for the prophylaxis and on-demand treatment of HAE attacks using deucrictibant. They have received FDA waivers for thorough QT studies for both formulations of deucrictibant, indicating progress in their regulatory interactions. Financially, Pharvaris reported a decrease in cash reserves and an increase in R&D expenses, reflecting its ongoing investment in clinical trials. The announcement underscores Pharvaris’ commitment to expanding treatment options for bradykinin-mediated angioedema and maintaining financial discipline.

The most recent analyst rating on (PHVS) stock is a Buy with a $31.00 price target. To see the full list of analyst forecasts on Pharvaris stock, see the PHVS Stock Forecast page.

Spark’s Take on PHVS Stock

According to Spark, TipRanks’ AI Analyst, PHVS is a Neutral.

Pharvaris exhibits significant financial difficulties, with no revenue and ongoing losses, resulting in a low financial performance score. Despite some technical momentum, the valuation is poor due to negative earnings. The stock’s overall score is affected by these financial and valuation challenges, despite its technical strength.

To see Spark’s full report on PHVS stock, click here.

More about Pharvaris

Pharvaris is a late-stage biopharmaceutical company focused on developing novel, oral bradykinin B2 receptor antagonists. Their primary aim is to address unmet needs in treating bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH). The company is working on providing oral therapies that offer injectable-like efficacy and placebo-like tolerability.

Average Trading Volume: 64,063

Technical Sentiment Signal: Hold

Current Market Cap: $916M

For a thorough assessment of PHVS stock, go to TipRanks’ Stock Analysis page.